<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Diabetes Mellitus | The Pharm Bible</title>

  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600&family=Parisienne&display=swap" rel="stylesheet">
  <link rel="stylesheet" href="style.css">
</head>
<body>

<header>
  <h1 class="main-title">Diabetes Mellitus</h1>
  <p class="subtitle">Type 1 & Type 2</p>
</header>

<main class="disease-page">

  <!-- GUIDELINES -->
  <section>
    <h2>Guidelines</h2>
    <ul class="guidelines">
      <li>
        <a href="https://diabetesjournals.org/care/issue/47/Supplement_1" target="_blank">
          American Diabetes Association – Standards of Care 2024
        </a>
      </li>
      <li>
        <a href="https://www.aace.com/disease-state-resources/diabetes" target="_blank">
          American Association of Clinical Endocrinology – 2023 Algorithm
        </a>
      </li>
      <li>
        <a href="https://www.ahajournals.org" target="_blank">
          American Heart Association – Cardiovascular Risk in Diabetes
        </a>
      </li>
    </ul>
  </section>

  <!-- PATHOPHYSIOLOGY -->
  <section>
    <h2>Pathophysiology</h2>

    <h3>Type 1 Diabetes</h3>
    <ul>
      <li>Autoimmune beta-cell destruction</li>
      <li>Absolute insulin deficiency</li>
      <li>High risk of diabetic ketoacidosis (DKA)</li>
    </ul>

    <div class="image-placeholder">[Insert Type 1 Pathophysiology Image Here]</div>

    <h3>Type 2 Diabetes</h3>
    <ul>
      <li>Insulin resistance</li>
      <li>Progressive beta-cell dysfunction</li>
      <li>Relative insulin deficiency</li>
    </ul>

    <div class="image-placeholder">[Insert Type 2 Pathophysiology Image Here]</div>

  </section>

  <!-- TREATMENT ALGORITHM -->
  <section>
    <h2>Treatment Algorithm</h2>

    <h3>Type 1</h3>

    <div class="flowchart">
      <div class="flow-box">Diagnosis of Type 1 Diabetes</div>
      <div class="flow-arrow">↓</div>
      <div class="flow-box">Initiate Basal + Bolus Insulin</div>
      <div class="flow-arrow">↓</div>
      <div class="flow-box">Consider CGM / Insulin Pump</div>
      <div class="flow-arrow">↓</div>
      <div class="flow-box">A1c Goal &lt; 7% (Individualize)</div>
    </div>

    <h3>Type 2 (ADA-Based)</h3>

    <div class="flowchart">

      <div class="flow-box">Start Lifestyle + metformin (if not contraindicated)</div>
      <div class="flow-arrow">↓</div>

      <div class="flow-box">Assess Comorbidities</div>

      <div class="branch-container">

        <div class="flow-branch">
          <div class="branch-title">ASCVD</div>
          <div class="flow-box small">GLP-1 RA OR SGLT2 inhibitor (CV benefit)</div>
        </div>

        <div class="flow-branch">
          <div class="branch-title">Heart Failure</div>
          <div class="flow-box small">SGLT2 inhibitor preferred</div>
        </div>

        <div class="flow-branch">
          <div class="branch-title">CKD</div>
          <div class="flow-box small">SGLT2 inhibitor if eGFR adequate</div>
        </div>

        <div class="flow-branch">
          <div class="branch-title">Weight Priority</div>
          <div class="flow-box small">GLP-1 RA preferred</div>
        </div>

      </div>

      <div class="flow-arrow">↓</div>
      <div class="flow-box">If A1c ≥ 10% OR symptomatic → Initiate Insulin</div>

    </div>

  </section>

  <!-- DRUG THERAPY -->

  <section>
    <h2>Drug Therapy</h2>

    <!-- BIGUANIDES -->
    <h3>Biguanides</h3>
    <table class="drug-table">
      <tr>
        <th>Drug</th>
        <th>Indication</th>
        <th>Dose</th>
        <th>MOA</th>
        <th>Side Effects</th>
        <th>Contraindications</th>
        <th>Pearls</th>
      </tr>
      <tr>
        <td>metformin (Glucophage, Glucophage XR)</td>
        <td>First-line Type 2</td>
        <td>500 mg BID → max 2000 mg/day</td>
        <td>↓ hepatic glucose production</td>
        <td>
          Common: GI upset<br>
          Serious: B12 deficiency<br>
          <u>Black Box:</u><br>
          Lactic acidosis
        </td>
        <td>eGFR &lt; 30</td>
        <td>Weight neutral; hold with contrast</td>
      </tr>
    </table>

    <!-- GLP-1 RA -->
    <h3>GLP-1 Receptor Agonists</h3>
    <table class="drug-table">
      <tr>
        <th>Drug</th>
        <th>Indication</th>
        <th>Dose</th>
        <th>MOA</th>
        <th>Side Effects</th>
        <th>Contraindications</th>
        <th>Pearls</th>
      </tr>
      <tr>
        <td>semaglutide (Ozempic, Wegovy, Rybelsus)</td>
        <td>T2DM; weight loss</td>
        <td>0.25 mg weekly → titrate</td>
        <td>↑ insulin, ↓ glucagon, slows gastric emptying</td>
        <td>
          Common: Nausea<br>
          Serious: Pancreatitis<br>
          <u>Black Box:</u><br>
          Thyroid C-cell tumors
        </td>
        <td>MEN2 or MTC history</td>
        <td>CV benefit; strong weight loss</td>
      </tr>
    </table>

  </section>

</main>

</body>
</html>
